

CITATION REPORT

List of articles citing

Response-Guided Therapy: Optimizing Treatment now and in the Future

DOI: 10.1177/135965350801301806
Antiviral Therapy, 2008, 13, 1-2.

Source: <https://exaly.com/paper-pdf/145834033/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
187	Current awareness: Pharmacoepidemiology and drug safety. 2008 , 17, i-xvi		
186	Ritonavir-boosted darunavir: a powerful option for treatment-experienced HIV-1-infected patients. <i>Future Virology</i> , 2008 , 3, 423-434	2.4	
185	Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance. 2009 , 5, 563-78		6
184	Surveillance of HIV type 1 drug resistance among naive patients from Venezuela. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 1329-33	1.6	7
183	Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 33-6	5.1	30
182	Update on HIV viral-load assays: new technologies and testing in resource-limited settings. <i>Future Virology</i> , 2009 , 4, 423-430	2.4	5
181	Transplacental passage of ritonavir-boosted darunavir in two pregnant women. 2009 , 20, 215-6		19
180	The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. 2009 , 25, 1197-8		134
179	Transmitted drug resistance in nonsubtype B HIV-1 infection. 2009 , 3, 447-465		27
178	Paradigm shift to address drug resistant tuberculosis in people living with HIV needed, and needed now. 2009 , 14, 376-8		
177	Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. 2009 , 68, 116-9		11
176	Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. 2009 , 103, 607-12		15
175	Darunavir: a review of its use in the management of HIV infection in adults. 2009 , 69, 477-503		95
174	Impact of the global economic crisis on antiretroviral treatment programs. 2009 , 3, 545-548		
173	Re-thinking global health sector efforts for HIV and tuberculosis epidemic control: promoting integration of programme activities within a strengthened health system. 2010 , 10, 394		11
172	Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. 2010 , 10, 430		27
171	Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia. 2010 , 82, 2013-8		10

170	A comparative analysis of the fluorescence properties of the wild-type and active site mutants of the hepatitis C virus autoprotease NS2-3. 2010 , 1804, 212-22		6
169	Stable and low prevalence of transmitted HIV type 1 drug resistance despite two decades of antiretroviral therapy in Hong Kong. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 1079-85	1.6	16
168	Transmitted HIV drug resistance among HIV-infected voluntary counseling and testing centers (VCTC) clients in Mumbai, India. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 927-32	1.6	20
167	Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. 2010 , 5, 298-304		132
166	HIV diagnostics: challenges and opportunities. 2010 , 4, 399-412		8
165	Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 343-50	6.2	16
164	Darunavir: in treatment-experienced pediatric patients with HIV-1 infection. 2010 , 12, 123-31		5
163	Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. 2010 , 49, 239-44		20
162	[AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)]. 2010 , 28, 362.e1-91		10
161	Antiretroviral drug resistance in HIV-infected patients in Colombia. 2010 , 14, e298-303		13
160	Should microbicides be controlled by women or by physicians?. 2010 , 14 Suppl 3, e14-7		3
159	Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. 2010 , 376, 1838-45		905
158	Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. 2010 , 10, 155-66		232
157	Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 5-12	1.6	99
156	Drug interactions of new antiretroviral drugs. 2011 , 35, 36-43		
155	HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. <i>PLoS ONE</i> , 2011 , 6, e23091	3.7	34
154	Retention on Antiretroviral Therapy in National Programs in Low-Income and Middle-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e102-e103	3.1	
153	Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. 2011 , 25, 905-10		52

152	Point-of-care nucleic acid testing for infectious diseases. 2011 , 29, 240-50		591
151	Drug interactions of new antiretroviral drugs. 2011 , 35, 36-43		2
150	Resistance to antiretroviral drugs in newly diagnosed, young treatment-naïve HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. 2011 , 83, 1508-13		20
149	Implementation and outcomes of an active defaulter tracing system for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB patients in Kibera, Nairobi, Kenya. 2011 , 105, 320-6		42
148	Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. 2011 , 6, 1251-60		27
147	Darunavir: an effective protease inhibitor for HIV-infected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2011 , 9, 631-43	5.5	7
146	Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2011 , 52, 1267-75	11.6	101
145	Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1573-81	5.1	20
144	Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2290-6	5.9	32
143	Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3613-5	5.9	9
142	Drug resistance surveillance in resource-poor settings: current methods and considerations for TB, HIV, and malaria. 2011 , 84, 192-9		17
141	Resistance to antiretroviral drugs in treated and drug-naïve patients in the Democratic Republic of Congo. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 57 Suppl 1, S27-33	3.1	24
140	Drug resistance mutations in HIV type 1 isolates from naïve patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 1345-7	1.6	14
139	Experience in piloting HIV drug resistance early warning indicators to improve the antiretroviral program in Papua New Guinea. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S303-5	11.6	7
138	Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy. 2012 , 11, 203-9		12
137	A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S355-61	11.6	14
136	HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis. <i>Clinical Infectious Diseases</i> , 2012 , 55, 303-4; author reply 304	11.6	24
135	Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 671-4	5.1	22

134	Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1187-95	11.6	45
133	Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S273-9	11.6	24
132	Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S317-9	11.6	8
131	Are countries using global fund support to implement HIV drug resistance surveillance? A review of funded HIV grants. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S250-3	11.6	
130	HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S280-9	11.6	44
129	Combining cohort analysis and monitoring of HIV early-warning indicators of drug resistance to assess antiretroviral therapy services in Vietnam. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S306-12	11.6	26
128	Primary drug resistance in South Africa: data from 10 years of surveys. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 558-65	1.6	45
127	Therapeutic Drug Monitoring of Antiretroviral Drugs in the Management of Human Immunodeficiency Virus Infection. 2012 , 373-396		
126	Transmitted drug resistance among antiretroviral-naïve patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 667-74	1.6	18
125	The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. 2012 , 64, 803-33		78
124	Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S261-5	11.6	8
123	Monitoring HIV drug resistance using early warning indicators in China: results from a pilot survey conducted in 2008. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S300-2	11.6	9
122	Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S245-9	11.6	42
121	Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S294-9	11.6	22
120	Darunavir: a critical review of its properties, use and drug interactions. 2012 , 90, 102-9		21
119	Implementing early-warning indicators of HIV drug resistance in the Caribbean. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S290-3	11.6	6
118	Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S375-80	11.6	27
117	Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S334-8	11.6	34

116	Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. 2012 , 380, 1250-8		270
115	Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes. 2012 , 54, 21-5		12
114	Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S266-72	11.6	19
113	Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China. <i>BMC Infectious Diseases</i> , 2012 , 12, 382	4	28
112	Global HIV-1 diversity surveillance. 2012 , 18, 691-4		22
111	The origin and evolutionary history of HIV-1 subtype C in Senegal. <i>PLoS ONE</i> , 2012 , 7, e33579	3.7	18
110	Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. <i>Journal of the International AIDS Society</i> , 2012 , 15, 17985	5.4	37
109	Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings. 2013 , 13, 308		18
108	Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. 2013 , 207 Suppl 2, S49-56		95
107	Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. 2013 , 18, 125-31		43
106	The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings. 2013 , 207 Suppl 2, S45-8		20
105	Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India. 2013 , 17, 2253-9		15
104	Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing. <i>Journal of Virological Methods</i> , 2013 , 187, 314-20	2.6	10
103	Evaluations of an in-house drug resistance method for HIV-1 drug resistance using ViroSeq ^{2.0} genotyping system as a gold standard. <i>Journal of Virological Methods</i> , 2013 , 189, 87-92	2.6	5
102	Surveillance for human immunodeficiency virus/acquired immunodeficiency syndrome for countries in transition: PART 1: Surveillance for human immunodeficiency virus/acquired immunodeficiency syndrome in India. 2013 , 317-326		
101	Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 684-9	5.1	29
100	Gag-Pol processing during HIV-1 virion maturation: a systems biology approach. 2013 , 9, e1003103		35
99	Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. 2013 , 91, 377-385E		97

98	Transmitted HIV drug resistance in Asia. 2013 , 8, 27-33		18
97	Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 529-39	9.7	21
96	Comparison of Ahlstrom grade 226, Munktell TFN, and Whatman 903 filter papers for dried blood spot specimen collection and subsequent HIV-1 load and drug resistance genotyping analysis. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 55-60	9.7	18
95	Stability Study of Darunavir Ethanolate Tablets Applying a New Stability-Indicating HPLC Method. 2013 , 2013, 1-7		5
94	Baseline clinical HIV genotypes are a valid measure of transmitted drug resistance within the treatment-naive population. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 64, 443-7	3.1	4
93	Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa. <i>Journal of the International AIDS Society</i> , 2013 , 16, 18580	5.4	8
92	Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina. <i>Journal of the International AIDS Society</i> , 2013 , 16, 18519	5.4	7
91	HIV drug resistance early warning indicators in Namibia for public health action. <i>PLoS ONE</i> , 2013 , 8, e65653	5.3	6
90	Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients. <i>PLoS ONE</i> , 2013 , 8, e62057	3.7	17
89	HIV drug resistance early warning indicators in namibia with updated World Health Organization guidance. <i>PLoS ONE</i> , 2014 , 9, e100539	3.7	15
88	The prevalence of HIV-1 drug resistance among antiretroviral treatment naïve individuals in mainland China: a meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e110652	3.7	11
87	Field study of dried blood spot specimens for HIV-1 drug resistance genotyping. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 2868-75	9.7	23
86	Dried Blood Spot Specimens for Polymerase Chain Reaction in Molecular Diagnostics and Public Health Surveillance. 2014 , 32-39		0
85	Editorial commentary: monitoring early warning indicators for HIV drug resistance in South Africa: challenges and opportunities. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1615-7	11.6	2
84	HIV Drug Resistance in Mothers and Infants Following Use of Antiretrovirals to Prevent Mother-to-Child Transmission. 2014 , 1-21		
83	Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes. <i>Viruses</i> , 2014 , 6, 3855-72	6.2	9
82	Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe. <i>BioMed Research International</i> , 2014 , 2014, 102598	3	4
81	HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA. <i>HIV Medicine</i> , 2014 , 15, 135-43	2.7	10

80	Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food. <i>Clinical Pharmacology in Drug Development</i> , 2014 , 3, 346-52	2.3	8
79	Low prevalence of transmitted drug resistance of HIV-1 during 2008-2012 antiretroviral therapy scaling up in Southern Vietnam. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 66, 358-64 ¹	3.1	13
78	Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. <i>Clinical Infectious Diseases</i> , 2014 , 58, 99-109	11.6	70
77	Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 603-9	1.6	3
76	Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2591-605	5.1	23
75	The fate of ritonavir in the presence of darunavir. <i>International Journal of Pharmaceutics</i> , 2014 , 475, 214-26	2.6	20
74	A critical review of properties of darunavir and analytical methods for its determination. <i>Critical Reviews in Analytical Chemistry</i> , 2014 , 44, 16-22	5.2	9
73	Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. <i>BMC Infectious Diseases</i> , 2014 , 14, 181	4	25
72	Monitoring prevention or emergence of HIV drug resistance: results of a population-based foundational survey of early warning indicators in mainland Tanzania. <i>BMC Infectious Diseases</i> , 2014 , 14, 196	4	6
71	Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C. <i>Journal of Virological Methods</i> , 2014 , 210, 36-9	2.6	10
70	Antiretroviral therapy adherence strategies used by patients of a large HIV clinic in Lesotho. <i>Journal of Health, Population and Nutrition</i> , 2015 , 33, 10	2.5	11
69	Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses. <i>HIV Medicine</i> , 2015 , 16, 95-104	2.7	16
68	Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis. <i>Hepatology International</i> , 2015 , 9, 543-57	8.8	3
67	The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. <i>Clinical Infectious Diseases</i> , 2015 , 61, 403-8	11.6	73
66	Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 3816-22	5.9	15
65	Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015 , 27, 86-92	2.2	25
64	The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China. <i>Archives of Virology</i> , 2015 , 160, 2051-61	2.6	10
63	Darunavir/cobicistat once daily for the treatment of HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2015 , 13, 691-704	5.5	9

62	HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6824-33	5.9	41
61	Therapeutic drug monitoring in HIV-infected pregnant women with a focus on protease inhibitors. <i>Future Virology</i> , 2015 , 10, 915-922	2.4	
60	Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009-10. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 941-7	5.1	14
59	First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda. <i>Journal of the International AIDS Society</i> , 2016 , 19, 20773	5.4	15
58	Prevalence of HIV Antiretroviral Drug Resistance and Its Impacts on HIV-1 Virological Failures in Jiangsu, China: A Cross-Sectional Study. <i>BioMed Research International</i> , 2016 , 2016, 1752437	3	12
57	Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010. <i>BMC Research Notes</i> , 2016 , 9, 302	2.3	15
56	Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. <i>Lancet HIV</i> , 2016 , 3, e579-e591	7.8	65
55	Novel pH sensing semiconductor for point-of-care detection of HIV-1 viremia. <i>Scientific Reports</i> , 2016 , 6, 36000	4.9	19
54	HIV-1 Sequencing. 2016 , 59-76		
53	Interventions using mobile devices (phones, smart phones, or tablets) to improve adherence to treatment for HIV or tuberculosis. <i>The Cochrane Library</i> , 2016 ,	5.2	3
52	Chronic Effects of Ethanol and/or Darunavir/Ritonavir on U937 Monocytic Cells: Regulation of Cytochrome P450 and Antioxidant Enzymes, Oxidative Stress, and Cytotoxicity. <i>Alcoholism: Clinical and Experimental Research</i> , 2016 , 40, 73-82	3.7	15
51	Polymorphic stability of darunavir and its formulation. <i>Journal of Thermal Analysis and Calorimetry</i> , 2016 , 123, 2185-2190	4.1	10
50	Telaprevir-based therapy in patients coinfectd with chronic hepatitis C virus infection and HIV: INSIGHT study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 244-50	5.1	2
49	Evaluation of 4-thiazolidinone derivatives as potential reverse transcriptase inhibitors against HIV-1 drug resistant strains. <i>Bioorganic Chemistry</i> , 2017 , 71, 211-218	5.1	24
48	Promises and pitfalls of Illumina sequencing for HIV resistance genotyping. <i>Virus Research</i> , 2017 , 239, 97-105	6.4	18
47	Community Based Antiretroviral Treatment in Rural Zimbabwe. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 1185-1191	1.6	7
46	Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996-2012. <i>Infection Ecology and Epidemiology</i> , 2017 , 7, 1328964	4.3	5
45	An assessment of the relationship between the World Health Organization HIV drug resistance early warning indicators and HIV drug resistance acquisition. <i>HIV Medicine</i> , 2017 , 18, 342-353	2.7	2

44	Role of P-Glycoprotein Inhibitors in the Bioavailability Enhancement of Solid Dispersion of Darunavir. <i>BioMed Research International</i> , 2017 , 2017, 8274927	3	11
43	Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure. <i>PLoS ONE</i> , 2017 , 12, e0172960	3.7	13
42	Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1267-1293	6.2	17
41	An Affordable and Portable Thermocycler for Real-Time PCR Made of 3D-Printed Parts and Off-the-Shelf Electronics. <i>Analytical Chemistry</i> , 2018 , 90, 5563-5568	7.8	34
40	Drug-Drug Interactions Between PA-824 and Darunavir Based on Pharmacokinetics in Rats by LC-MS-MS. <i>Journal of Chromatographic Science</i> , 2018 , 56, 327-335	1.4	9
39	Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals. <i>Journal of the International AIDS Society</i> , 2018 , 21, e25032	5.4	14
38	Comparison of antiretroviral drug resistance among treatment-naive and treated HIV-infected individuals in Shiraz, Iran. <i>Archives of Virology</i> , 2018 , 163, 99-104	2.6	1
37	Multi-spectroscopic and molecular docking studies on the interaction of darunavir, a HIV protease inhibitor with calf thymus DNA. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2018 , 193, 14-22	4.4	44
36	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , 2018 , 19, 145-165	2.6	9
35	Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. <i>PLoS ONE</i> , 2018 , 13, e0200505	3.7	16
34	Virological failure among adolescents on ART, Harare City, 2017- a case-control study. <i>BMC Infectious Diseases</i> , 2018 , 18, 469	4	25
33	Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania. <i>BMC Pharmacology & Toxicology</i> , 2018 , 19, 66	2.6	1
32	HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013. <i>PLoS ONE</i> , 2018 , 13, e0205446	3.7	14
31	Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz034	1	1
30	Prevalence of HIV-1 transmitted drug resistance and viral suppression among recently diagnosed adults in So Paulo, Brazil. <i>Archives of Virology</i> , 2019 , 164, 699-706	2.6	6
29	Point-of-care viral load testing among adolescents and youth living with HIV in Haiti: a protocol for a randomised trial to evaluate implementation and effect. <i>BMJ Open</i> , 2020 , 10, e036147	3	2
28	Drug repurposing approach to fight COVID-19. <i>Pharmacological Reports</i> , 2020 , 72, 1479-1508	3.9	165
27	HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naïve blood donors in China. <i>Scientific Reports</i> , 2020 , 10, 7571	4.9	5

26	HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study. <i>BMC Infectious Diseases</i> , 2020 , 20, 4	4	19
25	Relationships Between Viral Load, Neuroimaging, and NP in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 87, 985-992	3.1	0
24	Development of novel darunavir amorphous solid dispersions with mesoporous carriers. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 159, 105700	5.1	5
23	What the Future Holds for Resistance in Developing Countries. 2010 , 37-57		4
22	Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs. 2014 , 339-360		3
21	HIV drug resistance surveillance using pooled pyrosequencing. <i>PLoS ONE</i> , 2010 , 5, e9263	3.7	25
20	Evaluation of three sampling methods to monitor outcomes of antiretroviral treatment programmes in low- and middle-income countries. <i>PLoS ONE</i> , 2010 , 5, e13899	3.7	10
19	National prevalence and trends of HIV transmitted drug resistance in Mexico. <i>PLoS ONE</i> , 2011 , 6, e27812	3.7	24
18	Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. <i>PLoS ONE</i> , 2011 , 6, e28184	3.7	83
17	Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. <i>PLoS ONE</i> , 2012 , 7, e33484	3.7	51
16	Evidence that HIV-1 CRF01_AE is associated with low CD4+T cell count and CXCR4 co-receptor usage in recently infected young men who have sex with men (MSM) in Shanghai, China. <i>PLoS ONE</i> , 2014 , 9, e89462	3.7	41
15	Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran. <i>PLoS ONE</i> , 2015 , 10, e0126955	3.7	18
14	Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda. <i>PLoS ONE</i> , 2015 , 10, e0145536	3.7	18
13	Response-guided therapy in Japanese chronic hepatitis C patients infected with genotype 1b and high viral load. <i>Acta Hepatologica Japonica</i> , 2009 , 50, 687-702	0.3	
12	Human Immunodeficiency Virus: Resistance to Antiretroviral Drugs in Developing Countries. 2010 , 75-94		1
11	Antiretroviral agents. 2010 , 427-451		
10	Darunavir. 2010 , 2824-2829		
9	Drug Interactions with Antiretrovirals for HIV Infection. 2011 , 425-470		

8	HIV Drug Resistance in Mothers and Infants Following Use of Antiretrovirals to Prevent Mother-to-Child Transmission. 2017 , 543-565		
7	Darunavir inhibits / species complex growth and increases the susceptibility of biofilms to antifungal drugs. <i>Journal of Medical Microbiology</i> , 2020 , 69, 830-837	3.2	0
6	Potential Drugs for Treating COVID-19 Infection. <i>International Journal of Infection</i> , 2020 , 7,	1.4	
5	Effects of Framingham 10-year cardiovascular risk score and viral load on brain integrity in persons with HIV.. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022 , 90,	3.1	0
4	Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. <i>Antiviral Therapy</i> , 2008 , 13, 95-100	1.6	21
3	Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. <i>Antiviral Therapy</i> , 2008 , 13, 25-36	1.6	169
2	World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. <i>Antiviral Therapy</i> , 2008 , 13, 49-57	1.6	32
1	Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. <i>Antiviral Therapy</i> , 2008 , 13, 9-16	1.6	22